A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) Wild-Type Metastatic Colorectal Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2019
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- 25 Mar 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 25 Mar 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Dec 2019.
- 25 Mar 2019 Status changed from recruiting to active, no longer recruiting.